The Morning Stiffness Drug: An Oral Pill Just Cut Arthritis Pain in Dogs by 43 Percent
Doges Editorial · 2026-05-20 · 5 min read
A pilot study of 21 arthritic dogs found that twice-daily oral piclidenoson cut pain scores nearly in half over 90 days — by targeting a receptor pathway that existing anti-inflammatory drugs don't touch. A Phase 2 trial is already enrolling.
There's a particular moment that dog owners learn to recognize — the pause on the stairs. The dog that used to launch itself onto the couch now stands at the first step and considers it. The one that sprinted to the door for every walk now takes a few deliberate seconds to get moving in the morning, working through stiffness that wasn't there a year ago. Osteoarthritis is quiet in its early stages. Then, one day, it isn't.
An oral drug called piclidenoson may change what comes after that moment. A pilot study published in May 2026 found that 90 days of twice-daily dosing reduced pain scores by nearly half in dogs with established OA — and it does it through a pathway that existing arthritis drugs completely bypass.
A Molecule From an Unexpected Direction
Piclidenoson is an A3 adenosine receptor agonist — a description that sounds remote from your dog's morning stiffness, but refers to something biologically precise. The A3 adenosine receptor is a cellular target involved in inflammation and pain signalling. It operates through pathways distinct from the ones that common anti-inflammatory drugs target. That distinction turns out to matter.
Most canine osteoarthritis drugs — NSAIDs, corticosteroids — work by broadly suppressing inflammation. They work, often well, but they carry risks with long-term use: gastrointestinal effects, kidney concerns, the need for regular bloodwork monitoring that becomes its own management burden. A drug that reaches the same clinical destination via a different biochemical road may carry a different risk profile — which is precisely what researchers were investigating here.
Twenty-One Dogs, Ninety Days
The pilot study, published in Frontiers in Veterinary Science, enrolled 21 client-owned dogs — not laboratory animals, but real pets brought in by their owners with confirmed spontaneous osteoarthritis. Over 90 days, each dog received oral piclidenoson twice daily. Researchers tracked two validated measures: LOAD scores, a clinician-assessed evaluation of OA-related mobility limitations, and VAS pain scores rated by both owners and examining clinicians.
At enrollment, the mean LOAD score across the group was 25.4. After 90 days, it had dropped to 18.6 — a statistically significant reduction with a p-value below 0.001. The VAS pain scores told the same story: from a mean of 5.1 down to 2.9, also statistically significant at p<0.001.
A 27% reduction in a mobility-limitation score. A 43% reduction in pain score. In 90 days. In dogs with existing, confirmed OA. These are not marginal movements at the edge of clinical significance — they are the kind of numbers that earn a Phase 2 trial.
What LOAD Scores Actually Capture
The LOAD assessment — Liverpool Osteoarthritis in Dogs — is a multi-dimensional clinical evaluation of how OA affects a dog's function. It measures gait, ability to rise from rest, willingness to move on command, response to physical examination, and overall activity engagement. It is designed to capture the whole animal across daily life, not just one isolated measurement on a single examination day.
A score of 25 represents meaningful functional impairment — the dog that hesitates on stairs, that shortens its own walks, that stops engaging with play it used to seek out. A score of 18 means that impairment has measurably reduced. For the owners watching the dogs in this study over three months, those numbers corresponded to visible changes in how their animals moved through their days.
The Safety Picture
Adverse events in the pilot study were described as mild and transient. There were no serious adverse events attributed to the drug. This matters because efficacy and safety are not independent variables — the clinical value of a treatment depends on the combination of how well it works and what it costs the animal in side effects, especially for a drug intended for long-term daily use in older dogs.
The final data from the osteoarthritis study are very encouraging.
— Dr. Sari Fishman, VP Business Development, Can-Fite BioPharma
Can-Fite BioPharma, the Israeli biopharmaceutical company developing piclidenoson, has been pursuing the drug across multiple indications including human inflammatory diseases. Its mechanism — acting on the A3 receptor rather than the prostaglandin or COX pathways — means it occupies a pharmacological space that existing OA drugs leave entirely uncovered. If the Phase 2 data confirm what the pilot found, veterinarians would have a genuinely different class of option to offer.
A Phase 2 Already Enrolling
The Phase 2 trial is currently enrolling dogs, with results expected in the third quarter of 2026. Phase 2 trials involve larger populations, more rigorous controls, and the statistical power needed to confirm or complicate what a pilot study suggests. The word 'pilot' in a study title is a methodological description, not a dismissal — pilots exist precisely to determine whether a larger investment is warranted. The piclidenoson pilot suggests it clearly is.
Why This Matters Now
Osteoarthritis is one of the most common and undertreated conditions in veterinary medicine — affecting the majority of older dogs and with management options that remain imperfect for many animals.
— Frontiers in Veterinary Science, study background, 2026
Twenty-one dogs is a small number. The results are preliminary. The Phase 2 could complicate the picture in ways the pilot couldn't anticipate. All of that is true and should be held alongside the findings.
It is also true that OA affects an estimated 80% of dogs over eight years old. That current management options are imperfect — particularly for dogs that can't tolerate long-term NSAIDs. That the demand for new approaches is not hypothetical; it is playing out daily in households where a dog has learned to pause at the foot of the stairs.
An oral drug, given twice daily, with a favorable early safety profile, that works through a pathway current drugs don't touch, cutting pain scores by 43% in three months — that sentence is worth holding in mind as the Q3 data approach. With appropriate caution. But held.